Barrick Mining Corporation Stock Price, News & Analysis

BioArctic AB's partner Eisai announced the approval of Leqembi (lecanemab) for the treatment of Alzheimer's disease in the United Arab Emirates (UAE). The approval is based on the successful Phase 3 Clarity AD study, where Leqembi met its primary and key secondary endpoints. Leqembi is the first approved treatment shown to reduce disease progression and slow cognitive decline by targeting amyloid-beta aggregates in the brain.

In the UAE, 4.09% of those over 60 have dementia, with Alzheimer's being the most common cause. Leqembi is already approved in several countries, including the U.S., Japan, and China. The antibody was originally developed by BioArctic, based on research by Professor Lars Lannfelt. Eisai is responsible for clinical development and commercialization, with Biogen commercializing in the UAE.

Helzberg Diamonds, a renowned US jewelry retailer, has partnered with Proximity, creator of the award-winning Retail Super-App, to enhance customer experience. The collaboration aims to empower sales associates with a clienteling platform that delivers hyper-personalized service across all touchpoints. Launched in summer 2024, the platform connects customer data and uses innovative technology to power personalization and provide endless aisle capabilities.

The partnership is expected to transform customer engagement, drive repeat purchases, and increase in-store efficiency. Proximity's CEO, Cathy McCabe, expressed excitement about forging deep connections with customers and cultivating loyalty. Brad Hampton, CEO of Helzberg Diamonds, highlighted the opportunity to accelerate their digital transformation while maintaining the human touch that sets them apart in the industry.

ETQ, a Hexagon company, has unveiled the latest version of its ETQ Reliance® NXG quality management system (QMS) software, featuring a new Inspection Management app. This innovative solution automates and streamlines the quality inspection process for discrete and process manufacturers. The app enables:

- Automation of processes
- Reduction of paperwork
- Real-time visibility into quality operations

Key benefits include always-current prescriptive inspection guidance, automatic linking to quality events, a flexible inspection plan framework, and comprehensive data reporting and analytics. The Inspection Management app aims to mitigate the cost of poor quality, ensure compliance at scale, and maintain customer trust.

Crawford & Company (NYSE: CRD-A, CRD-B) reported its Q2 2024 results, with revenues before reimbursements at $314.2 million, down from $324.6 million in Q2 2023. Net income attributable to shareholders increased to $8.6 million from $8.4 million last year, with diluted EPS at $0.17 for both share classes, unchanged from Q2 2023. Non-GAAP diluted EPS rose to $0.25 from $0.24. The company added $23 million in new business, with a robust pipeline.

Segment Results:

• North America Loss Adjusting: Revenues of $76 million, slight decline; operating earnings up to $4.9 million.
• International Operations: Revenues up 7.3% to $102.3 million; operating earnings rose to $5.7 million.
• Broadspire: Record revenues of $97.1 million, up 11.3%; operating earnings surged to $15.1 million.
• Platform Solutions: Revenues fell 40.8% to $38.8 million; operating earnings down to $1.5 million.

Company's debt rose to $233.8 million, with cash and equivalents at $46.7 million. Cash used in operations was $8.3 million for H1 2024, versus $27.2 million provided in 2023. No CRD-A shares were repurchased, but 230,861 shares of CRD-B were repurchased for $2.1 million.

ETQ's global survey, The Pulse of Quality in Manufacturing 2024, reveals alarming trends in product recalls and promising developments in AI adoption. Key findings include:

- 73% of respondents experienced a product recall in the past five years, with costs reaching up to $99.9M per recall in the U.S.
- 47% plan to use AI in the next two years, while 33% are already using it
- 85% report that most or all plant floor workers have access to electronic devices
- 61% attribute up to half of product recalls to supplier issues
- 48% report 11-20 safety incidents annually

The survey, conducted by Censuswide, polled over 750 quality leaders across the U.S., U.K., and Germany. It highlights the growing role of frontline workers in decision-making and the strategic approach manufacturers are taking towards quality management.

BioArctic AB's partner Eisai reported that Leqembi® revenue more than doubled in Q2 2024, reaching JPY 6.3 billion, a 120% increase from Q1 2024 (JPY 2.8 billion). This resulted in a royalty of approximately SEK 43 million for BioArctic. Eisai leads Leqembi's development and regulatory submissions globally, with Eisai and Biogen co-commercializing the product. BioArctic has commercialization rights in the Nordic region and is preparing for joint commercialization with Eisai pending European approval. BioArctic's Q2 2024 report will be published on August 29, 2024, at 08:00 a.m. CET.

BioArctic AB's partner Eisai presented three-year data for lecanemab (Leqembi®) at the Alzheimer's Association International Conference 2024. Key findings include:

1. Increased patient benefit: Lecanemab reduced clinical decline by -0.95 on the CDR-SB scale after three years, up from -0.45 at 18 months.

2. Maintained safety profile: No new safety concerns observed over three years.

3. Early-stage patient improvement: 51% of patients with no or low tau showed improvement after three years.

4. Continued biomarker impact: Lecanemab positively affects biomarkers throughout treatment.

5. Tau spread reduction: Treatment slowed tau accumulation across brain regions.

These results suggest lecanemab's potential as a disease-modifying treatment for early Alzheimer's disease, with increasing benefits over time.

ETQ, part of Hexagon, achieved significant milestones in Q2 2024, reinforcing its leadership in the quality management system (QMS) market. Key highlights include:

1. Recognition: Named 'Overall Leader' among QMS suppliers by ABI Research.

2. Customer Growth: Added several new enterprise customers globally and expanded existing customer usage of ETQ Reliance®.

3. Industry Participation: Hosted the ETQ EU Summit and participated in major industry events like ASQ WCQI and Quality Show South.

4. Thought Leadership: ETQ executives shared insights at conferences and through industry publications.

These achievements demonstrate ETQ's commitment to innovation and customer satisfaction in the quality management landscape.

Barnes Aerospace has extended a long-term agreement with MTU Aero Engines AG, valued at $33 million. The deal involves Barnes Aerospace–Singapore OEM producing precision fabricated components for Pratt and Whitney's A320neo / A220 and Gulfstream G500 / G600 engines. This extension aligns with Barnes Aerospace's growth strategy to scale operations through deeper customer relationships and diverse capabilities.

The agreement highlights Barnes Aerospace's position as a key supplier in the industry, leveraging its high-precision technologies for high-volume production. Ian Reason, Senior VP of Barnes and President of Barnes Aerospace, emphasized the company's focus on operational and commercial excellence, which has led to MTU Aero Engines' continued confidence in their partnership.